Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04305795 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | Rakuten Medical, Inc.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | active not recruiting | Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 |
| clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03854032 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 45 | Thomas Jefferson UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05555862 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL(anal HSIL HIV-) | active not recruiting | Phase 2 | 17 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT04666090 | Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 42 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02998385 | Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)(SANTAL) | active not recruiting | Phase 3 | 342 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02999087 | Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)(REACH) | active not recruiting | Phase 3 | 707 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03576417 | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck(NIVOPOSTOP) | active not recruiting | Phase 3 | 680 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03726775 | Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN(REWRITe) | active not recruiting | Phase 2 | 61 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05527782 | Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 2 | 40 | Hospital Universitario Doctor PesetOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05674526 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | active not recruiting | Phase 1 | 30 | Allotera TherapeuticsINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04651634 | MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients(MIT-001) | active not recruiting | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT05987579 | Surgical Treatment of Stage T3 Squamous Cell Carcinomas of the Scalp | active not recruiting | — | 104 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06014619 | Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs | active not recruiting | — | 500 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06046625 | Needs and Preferences of Patients With Head-neck Cutaneous SCC | active not recruiting | — | 15 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03498378 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 24 | Kathryn GoldOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04632433 | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 25 | Fondazione Melanoma OnlusOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04001543 | Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer(SIMPA01) | active not recruiting | N/A | 27 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer(CERPASS) | active not recruiting | Phase 2 | 231 | Replimune, Inc.INDUSTRY | 10 | Jan 27, 2025 | clinicaltrials |
| NCT05202860 | Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis(VAXAK) | active not recruiting | Phase 2 | 70 | Merete HaedersdalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06762158 | NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC | active not recruiting | N/A | 50 | RenJi HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06699316 | Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall)(ProCoPall) | active not recruiting | N/A | 160 | Erasmus Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02653118 | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | active not recruiting | — | 4,453 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03813836 | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC(POPPY) | active not recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04452032 | Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer(StomRay) | active not recruiting | Phase 2 | 40 | Jules Bordet InstituteOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06616909 | Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences | active not recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05724329 | Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | active not recruiting | Phase 2 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04638465 | De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma | active not recruiting | — | 150 | Nebraska Methodist Health SystemOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04764227 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | active not recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05951127 | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC(LEO) | active not recruiting | N/A | 141 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05904327 | Circulating Biomarkers in Oropharyngeal Cancers(CIRCOS) | active not recruiting | — | 130 | Region Örebro CountyOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | active not recruiting | Phase 3 | 1,590 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05459415 | Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC | active not recruiting | N/A | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT01688908 | Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)(ESECC) | active not recruiting | N/A | 33,948 | Peking UniversityOTHER | 1 | Jan 23, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jun 19, 2025source: clinicaltrials